M1 Kliniken AG

  • WKN: A0STSQ
  • ISIN: DE000A0STSQ8
  • Land: Deutschland

Nachricht vom 10.09.2018 | 18:23

M1 Kliniken AG: M1 Kliniken AG decides to implement a cash capital increase using the authorized capital with exclusion of subscription rights in the amount of up to 10% of the share capital to finance further growth investments

M1 Kliniken AG / Key word(s): Corporate Action/Capital Increase
M1 Kliniken AG: M1 Kliniken AG decides to implement a cash capital increase using the authorized capital with exclusion of subscription rights in the amount of up to 10% of the share capital to finance further growth investments

10-Sep-2018 / 18:23 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


The Management Board of M1 Kliniken AG (ISIN: DE000A0STSQ8, WKN: A0STSQ) today decided to increase the company's share capital by up to 10% against cash contributions on the basis of the authorization granted by the Annual General Meeting on July 10,2018 by partially utilizing the authorized capital 2018. The Supervisory Board has approved the Management Board's decision.
 
The share capital of the company is to be increased - by the partial utilization of the authorized capital 2018 of currently EUR 16,500,000.00 - by issuing up to 1,650,000 bearer shares to a total share capital of up to EUR 18,150,000.00. The new shares are to be eligible for dividends as of January 1,2018 and are to be offered to institutional investors by means of a placement procedure in accordance with the exemption provisions for private placements without a prospectus and included in the existing listing of the company's shares. The placement price will not be significantly lower than the market price.
 
The final placement volume and the placement share price will be determined by the Management Board, with the approval of the Supervisory Board, after the placement procedure has been completed and will be announced in a separate ad hoc announcement.
 
M1 Kliniken AG intends to use the proceeds from the capital increase to finance its expansion into new medical indications as well as the opening of additional M1-locations in Germany and abroad.
 
M1 Kliniken AG
The Board of Directors
 
 
About M1 Kliniken AG
M1 Kliniken AG is the leading private provider of health care services in the field of beauty medicine in Germany. In the field of aesthetic and surgical treatments, the Group offers products and services of the highest quality standards. Under the brand names "M1 Med Beauty" and "M1 Dental", a network of currently 20 ambulatory specialist centres for beauty treatments and a surgical clinic is operated. With six operating theatres and 35 beds, the M1 Schlossklinik Berlin is one of the largest and most modern facilities of ist kind in Europe. The Group also markets high-quality products to doctors, pharmacies and wholesalers.
 
 
Important information:
The information contained in this document is not intended for distribution or publication in the United States (including its territories and possessions), Australia, Canada or Japan or any other country where such publication may be illegal.
 
This document does not constitute an offer to sell or a solicitation of an offer to purchase any securities.
 
In particular, this document does not constitute an offer to purchase securities in the United States of America. Securities may not be sold or sold in the United States of America without prior registration under the U. S. Securities may not be sold or sold in the United States of America without prior registration. Securities Act of 1933, as amended or without prior registration, are sold or offered for sale only on the basis of a derogation. The shares of M1 Kliniken AG are not and will not be sold in accordance with the regulations of the U. S. Securities Act of 1933, as amended, and will not be offered or sold in the United States of America.
 
In the member states of the European Economic Area that have implemented the Prospectus Directive, this document is addressed exclusively to "qualified investors" within the meaning of the Prospectus Directive 2003/71/EC (including all amendments, in particular to Directive 2010/73/EC) together with all relevant implementing measures in the relevant member states.




Contact:
Patrick Brenske, Management Board
Corporate Communications
E-Mail: ir@m1-kliniken.de

10-Sep-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Media and Games Invest wächst dynamisch und profitabel

Innerhalb des Konzerns Media and Games Invest sind der wachstumsstarke Game-Publisher gamigo AG sowie Unternehmen aus dem dynamischen Bereich „Digital Media“ gebündelt. Der Wachstumskurs der Gesellschaft soll sowohl auf Basis eines anhaltenden anorganischen Wachstums sowie durch den Ausbau des bestehenden Geschäftes fortgesetzt werden. Im Rahmen unserer Initial-Coverage-Studie haben wir ein Kursziel von 1,90 € je Aktie ermittelt und vergeben das Rating KAUFEN..

News im Fokus

Vonovia SE: Wohnungsunternehmen Vonovia erhält erstmalig A- Rating (News mit Zusatzmaterial)

13. Dezember 2019, 10:50

Aktuelle Research-Studie

MBH Corporation Plc

Original-Research: MBH Corporation plc (von GBC AG): Management Interview

13. Dezember 2019